Determination that CYANOCOBALAMIN INJECTION, 1 Milligram per Milliliter in a 10 Milliliter Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 14002-14003 [2017-05246]
Download as PDF
14002
Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices
Type of respondents
Law
Law
Law
Law
Enforcement
Enforcement
Enforcement
Enforcement
Officers
Officers
Officers
Officers
Number of
respondents
Form name
................
................
................
................
Average
burden per
response
(in hrs)
Number of
responses per
respondent
Total burden
(in hrs)
333
333
333
333
1
1
1
1
1/60
3/60
5/60
30/60
6
17
28
167
Law Enforcement Officers ................
Pre-Enrollment Confirmation Email ..
Biographical Information ..................
Consent form ....................................
Traditional anthropometric measurements.
2D and 3D scans .............................
333
1
30/60
167
Total ...........................................
...........................................................
........................
........................
........................
385
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
Dated: March 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–05265 Filed 3–15–17; 8:45 am]
[FR Doc. 2017–05247 Filed 3–15–17; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Food and Drug Administration
[Docket No. FDA–N–2016–4198]
[Docket No. FDA–2016–P–1676]
Public Meeting on Patient-Focused
Drug Development for Sarcopenia;
Request for Comments; Correction
Determination that
CYANOCOBALAMIN INJECTION, 1
Milligram per Milliliter in a 10 Milliliter
Vial, Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
AGENCY:
Notice; correction.
The Food and Drug
Administration is correcting a notice
entitled ‘‘Public Meeting on PatientFocused Drug Development for
Sarcopenia’’ that appeared in the
Federal Register of December 14, 2016
(81 FR 90361). The document
announced a public meeting and an
opportunity for public comment on
Patient-Focused Drug Development for
Sarcopenia. The location of the meeting
has changed and this document
provides the updated meeting location.
FOR FURTHER INFORMATION CONTACT:
Meghana Chalasani, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 1146,
Silver Spring, MD 20993–0002, 240–
402–6525, FAX: 301–847–8443,
Meghana.Chalasani@fda.hhs.gov.
In the Federal Register of Wednesday,
December 14, 2016, in FR Doc. 2016–
29998, the following correction is made:
1. On page 90361, in the second
column, in the first sentence of the
ADDRESSES section, ‘‘FDA White Oak
Campus, 10903 New Hampshire Ave.,
Bldg. 31 Conference Center, the Great
Room, (Rm. 1503), Silver Spring, MD
20993–0002.’’ is corrected to read
‘‘Tommy Douglas Conference Center,
mstockstill on DSK3G9T082PROD with NOTICES
17:12 Mar 15, 2017
Food and Drug Administration,
HHS.
SUMMARY:
VerDate Sep<11>2014
10000 New Hampshire Ave., Silver
Spring, MD 20903.’’
Jkt 241001
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) has
determined that CYANOCOBALAMIN
INJECTION, 1 milligram per milliliter in
a 10 milliliter vial, was not withdrawn
from sale for reasons of safety or
effectiveness. This determination means
that FDA will not begin procedures to
withdraw approval of abbreviated new
drug applications (ANDAs) that refer to
this drug product, and it will allow FDA
to continue to approve ANDAs that refer
to the product as long as they meet
relevant legal and regulatory
requirements.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Trentacost, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6219,
Silver Spring, MD 20993–0002, 240–
402–7736.
SUPPLEMENTARY INFORMATION: In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products under an
ANDA procedure. ANDA applicants
SUMMARY:
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
must, with certain exceptions, show that
the drug for which they are seeking
approval contains the same active
ingredient in the same strength, dosage
form, and route of administration as the
‘‘listed drug,’’ which is a version of the
drug that was previously approved.
ANDA applicants do not have to repeat
the extensive clinical testing otherwise
necessary to gain approval of a new
drug application (NDA).
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations,’’
which is known generally as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are removed from the list if the
Agency withdraws or suspends
approval of the drug’s NDA or ANDA
for reasons of safety or effectiveness or
if FDA determines that the listed drug
was withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to
determine, or the Agency may
determine on its own initiative, whether
a listed drug was withdrawn from sale
for reasons of safety or effectiveness.
This determination may be made at any
time after the drug has been withdrawn
from sale, but must be made prior to
approving an ANDA that refers to the
listed drug (21 CFR 314.161). FDA may
not approve an ANDA that does not
refer to a listed drug.
CYANOCOBALAMIN INJECTION, 1
milligram per milliliter in a 10 milliliter
vial, is the subject of ANDA 080557,
held by Fresenius Kabi USA (Fresenius),
and initially approved on June 20, 1973.
CYANOCOBALAMIN INJECTION is
indicated for vitamin B12 deficiencies
due to malabsorption that may be
associated with the following
conditions: Addisonian (pernicious)
anemia; gastrointestinal pathology,
dysfunction, or surgery, including
gluten enteropathy or sprue, small
bowel bacterial overgrowth, and total or
partial gastrectomy; fish tapeworm
E:\FR\FM\16MRN1.SGM
16MRN1
mstockstill on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices
infestation; malignancy of pancreas or
bowel; or folic acid deficiency.
In a letter dated December 21, 2016,
Fresenius notified FDA that
CYANOCOBALAMIN INJECTION, 1
milligram per milliliter in a 10 milliliter
vial, was discontinued over 30 years
ago, and Fresenius had concluded that
the drug was discontinued for reasons
other than safety or effectiveness.
Fresenius also conveyed that they
currently manufacture and market a 1
milliliter multiple dose vial of the 1
milligram per milliliter concentration.
John R. Rapoza submitted a citizen
petition dated June 16, 2016 (Docket No.
FDA–2016–P–1676), under 21 CFR
10.30, requesting that the Agency
determine whether
CYANOCOBALAMIN INJECTION, 1
milligram per milliliter in a 10 milliliter
vial, was withdrawn from sale for
reasons of safety or effectiveness.
After considering the citizen petition
and reviewing Agency records and
based on the information we have at this
time, FDA has determined under
§ 314.161 that CYANOCOBALAMIN
INJECTION, 1 milligram per milliliter in
a 10 milliliter vial, was not withdrawn
for reasons of safety or effectiveness.
The petitioner has identified no data or
other information suggesting that
CYANOCOBALAMIN INJECTION, 1
milligram per milliliter in a 10 milliliter
vial, was withdrawn for reasons of
safety or effectiveness. We have
carefully reviewed our files for records
concerning the withdrawal of
CYANOCOBALAMIN INJECTION, 1
milligram per milliliter in a 10 milliliter
vial, from sale. We have also
independently evaluated relevant
literature and data for possible
postmarketing adverse events. We have
reviewed the available evidence and
determined that this drug product was
not withdrawn from sale for reasons of
safety or effectiveness.
Accordingly, the Agency will list
CYANOCOBALAMIN INJECTION, 1
milligram per milliliter in a 10 milliliter
vial, in the ‘‘Discontinued Drug Product
List’’ section of the Orange Book. The
‘‘Discontinued Drug Product List’’
delineates, among other items, drug
products that have been discontinued
from marketing for reasons other than
safety or effectiveness. FDA will not
begin procedures to withdraw approval
of approved ANDAs that refer to this
drug product. Additional ANDAs for
this drug product may also be approved
by the Agency as long as they meet all
other legal and regulatory requirements
for the approval of ANDAs. If FDA
determines that labeling for this drug
product should be revised to meet
current standards, the Agency will
VerDate Sep<11>2014
17:12 Mar 15, 2017
Jkt 241001
advise ANDA applicants to submit such
labeling.
Dated: March 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–05246 Filed 3–15–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–D–0369]
Product-Specific Guidances for
Rifaximin; Revised Draft Guidance for
Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA, the Agency, or
we) is announcing the availability of a
revised draft guidance for industry on
generic rifaximin oral tablets entitled
‘‘Draft Guidance on Rifaximin.’’ The
revised draft guidance, when finalized,
will provide product-specific
recommendations on, among other
things, the design of bioequivalence
(BE) studies to support abbreviated new
drug applications (ANDAs) for rifaximin
oral tablets.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by May 15, 2017.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
14003
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2007–D–0369 for ‘‘Draft Guidance on
Rifaximin.’’ Received comments will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ will be publicly viewable
at https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
E:\FR\FM\16MRN1.SGM
16MRN1
Agencies
[Federal Register Volume 82, Number 50 (Thursday, March 16, 2017)]
[Notices]
[Pages 14002-14003]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05246]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-P-1676]
Determination that CYANOCOBALAMIN INJECTION, 1 Milligram per
Milliliter in a 10 Milliliter Vial, Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) has
determined that CYANOCOBALAMIN INJECTION, 1 milligram per milliliter in
a 10 milliliter vial, was not withdrawn from sale for reasons of safety
or effectiveness. This determination means that FDA will not begin
procedures to withdraw approval of abbreviated new drug applications
(ANDAs) that refer to this drug product, and it will allow FDA to
continue to approve ANDAs that refer to the product as long as they
meet relevant legal and regulatory requirements.
FOR FURTHER INFORMATION CONTACT: Elizabeth Trentacost, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6219, Silver Spring, MD 20993-0002, 240-
402-7736.
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products under an ANDA procedure. ANDA applicants
must, with certain exceptions, show that the drug for which they are
seeking approval contains the same active ingredient in the same
strength, dosage form, and route of administration as the ``listed
drug,'' which is a version of the drug that was previously approved.
ANDA applicants do not have to repeat the extensive clinical testing
otherwise necessary to gain approval of a new drug application (NDA).
The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products With Therapeutic
Equivalence Evaluations,'' which is known generally as the ``Orange
Book.'' Under FDA regulations, drugs are removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness or if FDA determines that the listed
drug was withdrawn from sale for reasons of safety or effectiveness (21
CFR 314.162).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (21 CFR 314.161). FDA may not approve an ANDA that does not refer
to a listed drug.
CYANOCOBALAMIN INJECTION, 1 milligram per milliliter in a 10
milliliter vial, is the subject of ANDA 080557, held by Fresenius Kabi
USA (Fresenius), and initially approved on June 20, 1973.
CYANOCOBALAMIN INJECTION is indicated for vitamin B12
deficiencies due to malabsorption that may be associated with the
following conditions: Addisonian (pernicious) anemia; gastrointestinal
pathology, dysfunction, or surgery, including gluten enteropathy or
sprue, small bowel bacterial overgrowth, and total or partial
gastrectomy; fish tapeworm
[[Page 14003]]
infestation; malignancy of pancreas or bowel; or folic acid deficiency.
In a letter dated December 21, 2016, Fresenius notified FDA that
CYANOCOBALAMIN INJECTION, 1 milligram per milliliter in a 10 milliliter
vial, was discontinued over 30 years ago, and Fresenius had concluded
that the drug was discontinued for reasons other than safety or
effectiveness. Fresenius also conveyed that they currently manufacture
and market a 1 milliliter multiple dose vial of the 1 milligram per
milliliter concentration.
John R. Rapoza submitted a citizen petition dated June 16, 2016
(Docket No. FDA-2016-P-1676), under 21 CFR 10.30, requesting that the
Agency determine whether CYANOCOBALAMIN INJECTION, 1 milligram per
milliliter in a 10 milliliter vial, was withdrawn from sale for reasons
of safety or effectiveness.
After considering the citizen petition and reviewing Agency records
and based on the information we have at this time, FDA has determined
under Sec. 314.161 that CYANOCOBALAMIN INJECTION, 1 milligram per
milliliter in a 10 milliliter vial, was not withdrawn for reasons of
safety or effectiveness. The petitioner has identified no data or other
information suggesting that CYANOCOBALAMIN INJECTION, 1 milligram per
milliliter in a 10 milliliter vial, was withdrawn for reasons of safety
or effectiveness. We have carefully reviewed our files for records
concerning the withdrawal of CYANOCOBALAMIN INJECTION, 1 milligram per
milliliter in a 10 milliliter vial, from sale. We have also
independently evaluated relevant literature and data for possible
postmarketing adverse events. We have reviewed the available evidence
and determined that this drug product was not withdrawn from sale for
reasons of safety or effectiveness.
Accordingly, the Agency will list CYANOCOBALAMIN INJECTION, 1
milligram per milliliter in a 10 milliliter vial, in the ``Discontinued
Drug Product List'' section of the Orange Book. The ``Discontinued Drug
Product List'' delineates, among other items, drug products that have
been discontinued from marketing for reasons other than safety or
effectiveness. FDA will not begin procedures to withdraw approval of
approved ANDAs that refer to this drug product. Additional ANDAs for
this drug product may also be approved by the Agency as long as they
meet all other legal and regulatory requirements for the approval of
ANDAs. If FDA determines that labeling for this drug product should be
revised to meet current standards, the Agency will advise ANDA
applicants to submit such labeling.
Dated: March 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-05246 Filed 3-15-17; 8:45 am]
BILLING CODE 4164-01-P